← Human Trials & Peer-Reviewed Studies
Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes
Plain-language guide to PMID 40481478 (2025): placebo-controlled randomized controlled trial study of Orforglipron (Foundayo, non-peptide).
Key Facts
- PMID
- 40481478
- Journal
- Cardiovascular diabetology
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Wharton S et al. (10 authors)
- DOI
- 10.1186/s12933-025-02781-x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Orforglipron (Foundayo, non-peptide) in this randomized controlled trial publication.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
Using data from participants with available samples from Phase 2 trials of orforglipron in participants with T2D (N = 361) or with overweight or obesity without diabetes mellitus (N = 234), the researchers performed an exploratory analysis of changes in CV risk markers.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
The participants were allocated by chance, so the Orforglipron (Foundayo, non-peptide) group and the comparison group should start out alike.
Some participants received a placebo instead of Orforglipron (Foundayo, non-peptide), giving a reference point.
The change from baseline at 26 weeks (T2D study) or 36 weeks (obesity study) in blood pressure, lipids (cholesterol, triglycerides, Apolipoprotein B (ApoB), Apolipoprotein C3 (ApoC3), N-terminal pro-b-type natriuretic peptide (NT-pro-BNP), and inflammatory biomarkers (high-sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6)) were assessed.
What Was Measured
The subject headings attached to it are Biomarkers, Blood Glucose, Blood Pressure, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists and Heart Disease Risk Factors.
Author keywords: GLP-1, Obesity, Oral and Orforglipron.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Orforglipron (Foundayo, non-peptide).
Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2025 (Cardiovascular diabetology), a journal based in England.
More context: the Orforglipron (Foundayo, non-peptide) compound page, all human trials.
Our Notes on the Compound
Orforglipron (Foundayo, non-peptide): An oral small-molecule GLP-1 receptor agonist (not a peptide); FDA-approved as Foundayo on April 1, 2026 for chronic weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.